Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Bring Back SI Bob! -- Ignore unavailable to you. Want to Upgrade?

To: Francois Goelo who wrote (635)	2/28/2001 11:15:04 PM
From: Sir Auric Goldfinger	Respond to of 808

Hard to lose a job when you haven't got one. Heard about the 1,300 square foot chicken coop you live in (we have spys EVERYWHERE, even the KMANs) Ignore it, deny it, but you know you've been caught out. No wonder you fool around with POS OTCC BB touting- it really is the only job you can get.

To: Francois Goelo who wrote (635)	3/1/2001 12:33:36 PM
From: Sir Auric Goldfinger	Respond to of 808

Like I said we know exactly who you are and what you are: "Celera, Baylor to Map Rat DNA Under Joint Research Program By SCOTT HENSLEY Staff Reporter of THE WALL STREET JOURNAL In the most tangible demonstration so far of collaboration between public and private genome researchers, the National Institutes of Health has awarded $58 million in grants to Baylor College of Medicine and Celera Genomics Group to sequence the genetic code of the laboratory rat. Under the joint research program, Celera, a unit of Applera Corp., Norwalk, Conn., will receive about $21 million over two years to sequence DNA of the rodent. Baylor's Human Genome Sequencing Center in Houston will receive about $37 million over the same period to sequence and then assemble the decoded fragments from both groups into a map of the rat genetic code. This is the first grant by NIH to Celera and marks a turnabout in the relationship between the private and government sectors in DNA sequencing. The head of Celera, J. Craig Venter, left the NIH in 1992 to start a nonprofit research center devoted to genome sequencing free of government bureaucracy. His maverick approach to sequencing was questioned at the time by some, including former colleagues at the NIH. But his approaches have revolutionized and accelerated gene-hunting. Celera and the publicly funded Human Genome Project competed to map the entire human genome, and simultaneously published their results last month. The deal represents a logical next step in making use of the vast DNA sequencing capacity and expertise that was developed through the public and private efforts. The rat genome is of particular interest for researchers, especially in the drug industry. "The rat is the premier experimental model system in pharmacology," said Richard Gibbs, director of Baylor's genome center. He said that sequencing of rat DNA has already begun and that data developed over the next few months are likely to be immediately useful in academia and industry. The rat genome is virtually the same size as the human genome, and scientists believe both species have the same types of genes. Thus, experiments targeting genes in rats are expected to help researchers understand similar genes in humans. The collaboration on the rat genome will work to the benefit of public and private researchers, Dr. Venter said, adding, "There are no losers." Dr. Venter, president and chief scientific officer of Celera, said the drug industry is keen on rat data because the animal is the usual subject for the early toxicology studies needed to evaluate potential medicines. Further, Dr. Venter said, Celera probably wouldn't have pursued the rat genome alone because of the expense, so a public-private collaboration and NIH grant will "bring in revenues and ... make good utilization of our facilities." Separately, Celera is expected to announce Thursday a multiyear subscription agreement for the company's genetic databases with a consortium of 37 medical schools and research centers in New York state. Terms of the deal with the group, New York-based Academic Medicine Development Co., weren't disclosed. Typically, academic laboratories pay about $10,000 a year for the Celera data. Rockefeller University, Albert Einstein College of Medicine, Cold Spring Harbor Laboratory and Columbia University are among the AMDEC members that are expected to sign up. Celera said the agreement contemplates as many as 1,000 laboratories becoming active subscribers. If so, it would represent Celera's largest contract with academic researchers to date. Celera's tracking stock was up $2.35 to $43.50 in 4 p.m. New York Stock Exchange trading Wednesday.